A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer

Yi,Suqin; Zhuang,Yuan; Zhou,Jun; Ma,Haitao; Huang,Jianan; Wang,Lin; Zhu,Weidong; Kang,Suya; Guo,Linchuan; Guo,Feng

doi:10.3892/ijmm.2014.1789

A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer

Authors:
- Suqin Yi
- Yuan Zhuang
- Jun Zhou
- Haitao Ma
- Jianan Huang
- Lin Wang
- Weidong Zhu
- Suya Kang
- Linchuan Guo
- Feng Guo
View Affiliations

Affiliations: Central Laboratory, The First Affiliated Hospital of Soochow University, Suzhou 215006, P.R. China, Department of Cardiothoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, P.R. China, Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, P.R. China, Department of Special Requirements Ward, The First Affiliated Hospital of Soochow University, Suzhou 215006, P.R. China, Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215006, P.R. China
Published online on: May 28, 2014 https://doi.org/10.3892/ijmm.2014.1789
Pages: 464-474

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The detection of somatic epidermal growth factor receptor (EGFR) mutations is valuable when an appropriate therapy, either EGFR-tyrosine kinase inhibitor (TKI) therapy or chemotherapy, for patients with advanced non-small cell lung cancer (NSCLC) needs to be selected. Although it is well‑understood that EGFR mutation detection is significant for the decision‑making regarding treatment, no consensus on the methodology that should be the most preferebale for detecting mutations in clinical practice has been reached. The presence of false positives due to the technique carried out for mutation analysis affects the accurate estimation of response EGFR-TKI therapy. Furthermore, false negatives directly exclude the potential application of an EGFR-TKI. In the present study, we present the results of detecting EGFR mutations in individual sample types using three different low- or high-sensitivity techniques. We suggest that the choice of the method used should be made based on the type of the sample. Our results revealed that EGFR mutations were less frequently detected in bronchoscopic biopsies, regardless of the method used. However, the amplification refractory mutation system (ARMS) was optimal owing to the small amount of DNA prepared for biopsy. The cytology sample was a valuable alternative to traditional samples, given that a sensitive method for detecting mutations was used. For surgical resections, the testing method may be selected based on the expertise of each laboratory, but direct sequencing is highly recommended. We also suggest that two methods should be used sequentially (the screening and targeted methods) in clinical practice due to the presence of non-neglected discordance between any method from its own benefits and drawbacks.

View Figures

View References

1	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
2	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
3	Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
4	Lopez-Rios F, Angulo B, Gomez B, et al: Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol. 66:381–385. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ellison G, Zhu G, Moulis A, Dearden S, Speake G and McCormack R: EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 66:79–89. 2013. View Article : Google Scholar : PubMed/NCBI
6	Pirker R, Herth FJ, Kerr KM, et al: Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 5:1706–1713. 2010. View Article : Google Scholar : PubMed/NCBI
7	Beasley MB and Milton DT: ASCO provisional clinical opinion: epidermal growth factor receptor mutation testing in practice. J Oncol Pract. 7:202–204. 2011. View Article : Google Scholar : PubMed/NCBI
8	Ellison G, Donald E, McWalter G, et al: A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res. 29:1322010. View Article : Google Scholar : PubMed/NCBI
9	Wittwer CT: High-resolution DNA melting analysis: advancements and limitations. Hum Mutat. 30:857–859. 2009. View Article : Google Scholar : PubMed/NCBI
10	Do H, Krypuy M, Mitchell PL, Fox SB and Dobrovic A: High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 8:1422008. View Article : Google Scholar : PubMed/NCBI
11	Krypuy M, Newnham GM, Thomas DM, Conron M and Dobrovic A: High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 6:2952006. View Article : Google Scholar : PubMed/NCBI
12	Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar
13	Zhuang Y, Xu J, Ma H, et al: A sequential method of epidermal growth factor receptor mutation detection reduces false negatives: a new case with doublet mutations of L833V and H835L in China. Clin Lung Cancer. 14:295–300. 2013. View Article : Google Scholar
14	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
15	Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 28:744–752. 2010. View Article : Google Scholar : PubMed/NCBI
16	Keedy VL, Temin S, Somerfield MR, et al: American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 29:2121–2127. 2011. View Article : Google Scholar
17	Gazdar AF: Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test? Medicine (Baltimore). 90:168–170. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zhou Q, Zhang XC, Chen ZH, et al: Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 29:3316–3321. 2011. View Article : Google Scholar : PubMed/NCBI
19	Ikeda T, Nakamura Y, Yamaguchi H, et al: Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 13:369–74. 2012. View Article : Google Scholar : PubMed/NCBI
20	Ren JH, He WS, Yan GL, Jin M, Yang KY and Wu G: EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis. Environ Mol Mutagen. 53:78–82. 2012. View Article : Google Scholar
21	Angulo B, Conde E, Suarez-Gauthier A, et al: A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS One. 7:e438422012. View Article : Google Scholar : PubMed/NCBI
22	Liang Z, Zhang J, Zeng X, Gao J, Wu S and Liu T: Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer. 10:3762010. View Article : Google Scholar : PubMed/NCBI
23	Yang TY, Tsai CR, Chen KC, Hsu KH, Lee HM and Chang GC: Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene. J Clin Oncol. 29:e468–e469. 2011. View Article : Google Scholar : PubMed/NCBI
24	Goto K, Satouchi M, Ishii G, et al: An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 23:2914–2919. 2012. View Article : Google Scholar : PubMed/NCBI
25	Horiike A, Kimura H, Nishio K, et al: Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest. 131:1628–1634. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kimura H, Fujiwara Y, Sone T, et al: High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 97:642–648. 2006. View Article : Google Scholar : PubMed/NCBI
27	Kim HJ, Oh SY, Kim WS, et al: Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncol Lett. 5:271–276. 2013.PubMed/NCBI
28	Fassina A, Gazziero A, Zardo D, Corradin M, Aldighieri E and Rossi GP: Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol. 62:1096–1102. 2009. View Article : Google Scholar : PubMed/NCBI
29	He M, Capelletti M, Nafa K, et al: EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 18:1790–1797. 2012. View Article : Google Scholar : PubMed/NCBI
30	Leary AF, Castro DG, Nicholson AG, et al: Establishing an EGFR mutation screening service for non-small cell lung cancer-sample quality criteria and candidate histological predictors. Eur J Cancer. 48:61–67. 2012. View Article : Google Scholar : PubMed/NCBI
31	Liu Y, Liu B, Li XY, et al: A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-smal-cell lung cancer patients. J Exp Clin Cancer Res. 30:1112011. View Article : Google Scholar : PubMed/NCBI
32	Penzel R, Sers C, Chen Y, et al: EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German panel for mutation testing in NSCLC. Virchows Arch. 458:95–98. 2011. View Article : Google Scholar : PubMed/NCBI
33	Takano T, Ohe Y, Tsuta K, et al: Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. Clin Cancer Res. 13:5385–5390. 2007. View Article : Google Scholar
34	Gonzalez-Bosquet J, Calcei J, Wei JS, et al: Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers. PLoS One. 6:e145222011. View Article : Google Scholar : PubMed/NCBI
35	Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A and Messersmith WA: KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn. 12:43–50. 2010. View Article : Google Scholar : PubMed/NCBI